Nueva prueba para el cáncer de mama Toma de decisiones Individualizado de Tratamiento, una realidad
Ampliamente aclamada como la próxima frontera en los avances médicos, la promesa de la medicina personalizada se está convirtiendo en una realidad gracias a los avances en la comprensión de las bases moleculares de las enfermedades, como el cáncer de mama. Los científicos pueden ahora desarrollar tratamientos que se adaptan a los perfiles genéticos individuales, así como las pruebas para predecir cómo responderá un paciente a las terapias existentes. Hoy en día, algunas mujeres con cáncer de mama en fase inicial y sus médicos puedan tomar decisiones más informadas del tratamiento con el Oncotype Ensayo del Cáncer de Mama DX. Este servicio proporciona información cuantitativa sobre los genes del tumor individual de una mujer para generar una puntuación de recurrencia entre cero y 100, lo que indica si está en alto, intermedio o bajo riesgo para su cáncer regrese después del tratamiento. Oncotype DX está diseñado para pacientes con ganglios negativos , estrógeno cáncer de mama positivo para receptores que son susceptibles de ser tratados con la terapia hormonal. Aproximadamente la mitad de los 230.000 pacientes con diagnóstico de cáncer de mama en los Estados Unidos cada año caen en esta categoría, y se ofrecen con frecuencia el tratamiento con quimioterapia, un tratamiento ampliamente utilizado con efectos secundarios considerables. Los estudios clínicos muestran que la quimioterapia ha mejorado las tasas de supervivencia de los pacientes en sólo 4 de cada 100 pacientes, sin embargo, miles de mujeres siguen para elegir este tratamiento costoso y tóxico con sólo información limitada acerca de si podrían responder a ella. Un estudio reciente demostró que las mujeres con alta recurrencia Las puntuaciones son más propensos a beneficiarse de la quimioterapia, mientras que las mujeres con puntuaciones más bajas sólo se aprovechan mínima. Además, sólo el 25% de las mujeres se redujo en el grupo de alto riesgo, en comparación con 50% en el grupo de bajo riesgo, lo que indica que este tratamiento común no es apropiado para todos los pacientes. Elizabeth Sloan de la ciudad de Nueva York es uno de los muchos de mama pacientes con cáncer no propensos a responder a la quimioterapia. Una madre activa con dos hijos pequeños, Elizabeth estaba considerando tener otro hijo cuando le diagnosticaron en tan sólo 40 años de edad. Ella quería evitar la quimioterapia, con sus efectos secundarios a corto plazo perturbadores y potencialmente serias implicaciones a largo plazo, pero también quería estar absolutamente seguro de que no iba a ayudarla. Trabajar con su médico, Ruth Oratz, MD, Universidad de Nueva York Medical Center, Elizabeth decidió que el ensayo Oncotype DX, y estaba encantado cuando su puntuación de recurrencia resultó ser baja lo que indica que no puede beneficiarse significativamente de la quimioterapia. "No hay dos mujeres con cáncer de mama son exactamente iguales. Oncotype DX proporciona información que va más allá de las medidas estándar, como la edad, el tamaño del tumor y el grado tumoral, en la determinación de la probabilidad de recurrencia de la enfermedad ", dice el Dr. Oratz. "Oncotype DX dio Elizabeth y me añadió la confianza y la paz de la mente en la selección del tratamiento más apropiado para ella." Por Susan Bakken de Denver, Colorado, Oncotype DX proporciona un tipo diferente de la paz de la mente. Susan Recurrencia Score indicó que ella estaba en alto riesgo de recurrencia del cáncer, y que probablemente se beneficiarían significativamente de la quimioterapia tanto su sorpresa y su médico. "Sobre la base de las demás pruebas que tenía, mi doctor dijo que no habría recomendado lo contrario quimioterapia . Me quedé muy sorprendida al saber el resultado de mi, pero yo estaba tan contenta de haberlo hecho porque creo que esta prueba básicamente me salvó la vida ", explica Susan. Elizabeth Sloan también agradece la información que obtuvo de Oncotype DX. "No todos los cánceres son iguales, ¿por qué tratan a todos de la misma manera con algo tan tóxico?", Dijo. "Es muy notable que, finalmente, los médicos pueden diferenciar el cáncer de una persona de otra-estoy muy agradecido." Oncotype DX es una prueba simple que puede ser efectuado únicamente por un médico. Se lleva a cabo en una pequeña cantidad de tejido tumoral de mama extirpado durante una tumorectomía estándar, mastectomía o una biopsia, es decir, ningún procedimiento adicional se requiere
--------
Asistencia Sociosanitaria a Domicilio y Hospitales en Guipúzcoa - Gipuzkoa
Servicios de Ayuda a Domicilio Lagundu
---------
New Test For Breast Cancer Making Individualized Treatment Decisions A Reality
Widely hailed as the next frontier in medical advances, the promise of individualized medicine is becoming a reality thanks to progress in understanding the molecular basis of diseases such as breast cancer. Scientists can now develop treatments that are tailored to individual genetic profiles, as well as tests to predict how a patient will respond to existing therapies.
Today, some women with early-stage breast cancer and their physicians can make more informed treatment decisions with the Oncotype DX Breast Cancer Assay. This service provides quantitative information about genes from a woman's individual tumor to generate a Recurrence Score between zero and 100, indicating whether she is at high, intermediate or low risk for her cancer returning after treatment.
Oncotype DX is intended for patients with node-negative, estrogen receptor-positive breast cancer who are likely to be treated with hormonal therapy. Approximately half of the 230,000 patients diagnosed with breast cancer in the United States each year fall into this category, and are frequently offered treatment with chemotherapy, a widely used treatment with considerable side effects. Clinical studies show that chemotherapy improved patient survival rates in only 4 out of 100 patients, yet thousands of women continue to elect this costly and toxic treatment with only limited information about whether they might respond to it.
A recent study demonstrated that women with high Recurrence Scores are more likely to benefit from chemotherapy, whereas women with lower scores derive only minimal benefit. Further, only 25% of women fell into the high-risk group, compared to 50% in the low-risk group, indicating that this common treatment is not appropriate for every patient.
Elizabeth Sloan of New York City is one of the many breast cancer patients not likely to respond to chemotherapy. An active mother with two young boys, Elizabeth was considering having another child when she was diagnosed at just 40 years old. She wanted to avoid chemotherapy, with its disruptive, short-term side effects and potentially serious long-term implications, but also wanted to be absolutely certain that it wouldn't help her.
Working with her doctor, Ruth Oratz, M.D., at NYU Medical Center, Elizabeth decided to have the Oncotype DX assay, and was delighted when her Recurrence Score turned out to be low-indicating that she may not benefit significantly from chemotherapy.
"No two women with breast cancer are exactly alike. Oncotype DX provides information that goes beyond standard measures, like age, tumor size and tumor grade, in determining the likelihood of disease recurrence," says Dr. Oratz. "Oncotype DX gave Elizabeth and me added confidence and peace of mind in selecting the most fitting treatment for her."
For Susan Bakken of Denver, Colorado, Oncotype DX provided a different kind of peace of mind. Susan's Recurrence Score indicated that she was at high risk of cancer recurrence, and would likely benefit significantly from chemotherapy-to both her surprise and her doctor's.
"Based on the other tests I had, my doctor said he wouldn't have otherwise recommended chemotherapy. I was shocked to find out my result, but I was so glad I did because I believe this test basically saved my life," explained Susan.
Elizabeth Sloan is also grateful for the information she gained from Oncotype DX. "Not all cancers are the same, so why treat everyone the same way with something so toxic?" she said. "It's so remarkable that finally, doctors can distinguish one person's cancer from another-I'm just so thankful."
Oncotype DX is a simple test that can only be ordered by a physician. It is performed on a small amount of breast tumor tissue removed during a standard lumpectomy, mastectomy or biopsy, meaning no additional procedure is required.
Today, some women with early-stage breast cancer and their physicians can make more informed treatment decisions with the Oncotype DX Breast Cancer Assay. This service provides quantitative information about genes from a woman's individual tumor to generate a Recurrence Score between zero and 100, indicating whether she is at high, intermediate or low risk for her cancer returning after treatment.
Oncotype DX is intended for patients with node-negative, estrogen receptor-positive breast cancer who are likely to be treated with hormonal therapy. Approximately half of the 230,000 patients diagnosed with breast cancer in the United States each year fall into this category, and are frequently offered treatment with chemotherapy, a widely used treatment with considerable side effects. Clinical studies show that chemotherapy improved patient survival rates in only 4 out of 100 patients, yet thousands of women continue to elect this costly and toxic treatment with only limited information about whether they might respond to it.
A recent study demonstrated that women with high Recurrence Scores are more likely to benefit from chemotherapy, whereas women with lower scores derive only minimal benefit. Further, only 25% of women fell into the high-risk group, compared to 50% in the low-risk group, indicating that this common treatment is not appropriate for every patient.
Elizabeth Sloan of New York City is one of the many breast cancer patients not likely to respond to chemotherapy. An active mother with two young boys, Elizabeth was considering having another child when she was diagnosed at just 40 years old. She wanted to avoid chemotherapy, with its disruptive, short-term side effects and potentially serious long-term implications, but also wanted to be absolutely certain that it wouldn't help her.
Working with her doctor, Ruth Oratz, M.D., at NYU Medical Center, Elizabeth decided to have the Oncotype DX assay, and was delighted when her Recurrence Score turned out to be low-indicating that she may not benefit significantly from chemotherapy.
"No two women with breast cancer are exactly alike. Oncotype DX provides information that goes beyond standard measures, like age, tumor size and tumor grade, in determining the likelihood of disease recurrence," says Dr. Oratz. "Oncotype DX gave Elizabeth and me added confidence and peace of mind in selecting the most fitting treatment for her."
For Susan Bakken of Denver, Colorado, Oncotype DX provided a different kind of peace of mind. Susan's Recurrence Score indicated that she was at high risk of cancer recurrence, and would likely benefit significantly from chemotherapy-to both her surprise and her doctor's.
"Based on the other tests I had, my doctor said he wouldn't have otherwise recommended chemotherapy. I was shocked to find out my result, but I was so glad I did because I believe this test basically saved my life," explained Susan.
Elizabeth Sloan is also grateful for the information she gained from Oncotype DX. "Not all cancers are the same, so why treat everyone the same way with something so toxic?" she said. "It's so remarkable that finally, doctors can distinguish one person's cancer from another-I'm just so thankful."
Oncotype DX is a simple test that can only be ordered by a physician. It is performed on a small amount of breast tumor tissue removed during a standard lumpectomy, mastectomy or biopsy, meaning no additional procedure is required.
---
PLR Articles Packages eBooks Private Label Rights PLR Ebooks Packages Private Label Rights PLR Articles Pack Private Label Rights eBooks Private Label Rights Ebooks Master Resale Rights Articles Video Software Master Resale Rights SuperMegaPack Super MegaPack Mega Pack
--
Posts
